{"id":50688,"date":"2025-07-18T09:08:55","date_gmt":"2025-07-18T13:08:55","guid":{"rendered":"https:\/\/thestockmarketwatch.com\/stock-market-news\/moderna-scraps-japan-mrna-plant-amid-weakening-global-demand\/50688\/"},"modified":"2025-07-18T09:08:55","modified_gmt":"2025-07-18T13:08:55","slug":"moderna-scraps-japan-mrna-plant-amid-weakening-global-demand","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/moderna-scraps-japan-mrna-plant-amid-weakening-global-demand\/50688\/","title":{"rendered":"Moderna Scraps Japan mRNA Plant Amid Weakening Global Demand"},"content":{"rendered":"<ul>\n<li>\n<p><strong>Moderna (<a href=\"\/stock\/MRNA\">MRNA<\/a>) has announced the cancellation of its plans to construct a messenger RNA (mRNA) manufacturing facility in Japan, attributing the decision to a significant shift in the global and local business environment and prevailing weak demand.<\/strong> This move marks a strategic retreat from a previously intended expansion, highlighting the challenges faced by the biotechnology firm in a post-pandemic landscape.<\/p>\n<\/li>\n<li>\n<p>The cancellation comes as <strong>Moderna grapples with a substantial decline in revenue from its flagship COVID-19 vaccines<\/strong>, Spikevax, and a slower-than-anticipated adoption of its newly launched RSV vaccine, mRESVIA. The company had been banking on a diversified pipeline of new mRNA shots to offset the diminishing returns from its pandemic-era products.<\/p>\n<\/li>\n<li>\n<p>While the manufacturing plant plans are halted, <strong>Moderna confirmed that it has completed the construction of an mRNA drug research and manufacturing facility at the Shonan Health Innovation Park<\/strong>. This suggests a continued, albeit re-evaluated, commitment to research and development within Japan, with the company indicating it would reconsider manufacturing facilities if the business environment improves.<\/p>\n<\/li>\n<li>\n<p>The broader pharmaceutical industry is also navigating uncertainties, including <strong>concerns around regulations and policies<\/strong>, such as potential tariffs on pharmaceutical products. This external pressure, combined with the internal challenges of a saturated vaccine market, contributes to the &quot;poor business environment&quot; cited by Moderna.<\/p>\n<\/li>\n<li>\n<p>Despite this setback in manufacturing expansion, Moderna has been actively pursuing regulatory approvals for a range of mRNA-based products in Japan, including a next-generation COVID-19 jab and an RSV vaccine. The company also entered a joint agreement with Mitsubishi Tanabe Pharma Corporation in July 2024 to co-promote its mRNA respiratory vaccine portfolio in Japan, aiming for broad public health access.<\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Moderna (MRNA) has announced the cancellation of its plans to construct a messenger RNA (mRNA) manufacturing facility in Japan, attributing [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[1524,4817,5034,5127,5775,6015,6016,6017],"class_list":["post-50688","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-mrna","tag-manufacturing","tag-investment","tag-japan","tag-pharmaceuticals","tag-moderna","tag-biotechnology","tag-demand"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/50688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=50688"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/50688\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=50688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=50688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=50688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}